Last reviewed · How we verify
BI 1387446 200 μg
BI 1387446 200 μg is a Small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 development.
At a glance
| Generic name | BI 1387446 200 μg |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Hypertension
- Bradycardia
- Cataract
- Haemorrhoidal haemorrhage
- Asthenia
- Axillary pain
- Face oedema
- Oedema peripheral
- Pain
- Hyperbilirubinaemia
- Oral candidiasis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BI 1387446 200 μg CI brief — competitive landscape report
- BI 1387446 200 μg updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI
Frequently asked questions about BI 1387446 200 μg
What is BI 1387446 200 μg?
BI 1387446 200 μg is a Small molecule drug developed by Boehringer Ingelheim.
Who makes BI 1387446 200 μg?
BI 1387446 200 μg is developed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).
What development phase is BI 1387446 200 μg in?
BI 1387446 200 μg is in Phase 1.
What are the side effects of BI 1387446 200 μg?
Common side effects of BI 1387446 200 μg include Fatigue, Hypertension, Bradycardia, Cataract, Haemorrhoidal haemorrhage, Asthenia.
Related
- Manufacturer: Boehringer Ingelheim — full pipeline
- Compare: BI 1387446 200 μg vs similar drugs
- Pricing: BI 1387446 200 μg cost, discount & access